AbbVie has agreed to pay $1.4 billion to buy Aliada Therapeutics. The acquisition will give AbbVie control of an Alzheimer’s ...

The acquisition of Aliada Therapeutics will grant AbbVie access to a neuroscience-focused technology platform and an ...

The purchase of Aliada Therapeutics is “interesting for a number of reasons,” according to a Stifel analyst, one of which is ...

The acquisition will allow AbbVie to accelerate development of ALIA-1758, a potential disease-modifying therapy for Alzheimer ...

AbbVie and Aliada Therapeutics have announced a definitive agreement under which AbbVie will acquire Aliada, a biotechnology ...

Discover the major biotech partnerships, collaborations, and mergers and acquisitions that made headlines in October 2024.

AbbVie has boosted its Alzheimer's disease pipeline with a $1.4 billion cash deal to buy Aliada Therapeutics and its ...

U.S. drugmaker AbbVie said on Monday it will buy Aliada Therapeutics for $1.4 billion in cash, betting on an experimental ...

The acquisition of Aliada Therapeutics gives AbbVie access to a Phase I anti-amyloid antibody as well as the biotech’s novel ...

The purchase is the latest in a slew of efforts to invest in its neuroscience portfolio as Humira faces generic competition.

AbbVie (ABBV) to acquire Aliada Therapeutics for $1.4B in cash, enhancing focus on Alzheimer's disease with innovative ...

AbbVie (NYSE: ABBV) and Aliada Therapeutics today announced a definitive agreement under which AbbVie will acquire Aliada, a biotechnology company advancing therapies using a novel blood-brain barrier ...